Our Work

Upcoming Events

February 21-23

Location: Washington, DC

Who will be there: Jack Henningfield

March 8-11

Location: Florence, Italy

Who will be there: Joe Gitchell, Jack Henningfield, Saul Shiffman, Michael Hufford, Annie Kleykamp, Robyn Gougelet, Amy Arthur, Gabrielle Blythe

March 19-22

Location: Amelia Island, FL

Who will be there: John Pinney, Lucy Owen, Michael Hufford

April 6-9

Location: New Orleans, LA

Who will be there: Jack Henningfield

April 19-20

Location: Silver Spring, MD

Who will be there: Annie Kleykamp, Robyn Gougelet

May 4-5

Location: Washington, DC

Who will be there: Joe Gitchell, Robyn Gougelet

May 29-June 2

Location: Miami, FL

Who will be there: Jack Henningfield

otc-icon

Can consumers self-select for appropriate use of an over-the-counter statin? The Self Evaluation of Lovastatin to Enhance Cholesterol Treatment Study

Brass EP, Vassil T, Replogle A, Hwang P, Rusche S, Shiffman S, Levine JG

Consumer understanding of prescription drug information: An illustration using an antidepressant medication.

Shiffman S, Gerlach KK, Sembower M, Rohay JM

Consumers appropriately self-treat based on labeling for over-the-counter hydrocortisone

Ellis CN, Pillitteri J, Kyle TK, Ertischek MD, Burton SL, Shiffman S

Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability?

Shiffman S, Sweeney CT

perscription-icon

Abuse potential assessment of novel opioid analgesic NKTR-181: implications for labeling and scheduling

Webster LR, Smith S, Silowsky J, Gogas K, Odinecs A, Eldon M, Abrouk N, Medve R, Henningfield JE, Buchhalter AR, Cone EJ, Fant RV, Schnoll S

An iterative model for in vitro laboratory assessment of tamper deterrent formulations

Cone EJ, Giordano J, Weingarten B

Do prescription monitoring programs impact state trends in opioid abuse/misuse?

Reifler LM, Droz D, Bailey JE, Schnoll S, Fant RV, Dart RC, Bucher Bartelson B

Epidemiology of stimulant misuse and abuse: implications for future epidemiologic and neuropharmacologic research

Gerlach KK, Dasgupta N, Schnoll S, Henningfield JE

Establishing “abuse-deterrence equivalence” for generic abuse-deterrent opioid formulations: A proposed development framework

Setnik B, Cone EJ

Extreme work requirement of EG-001, an abuse-deterrent, extended-release morphine product, as demonstrated with the ALERRT® Visual Analog Scales.

Cone EJ, Buchhalter AR, Lindhardt K, Elhauge T, Dayno JM

Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse

Sweeney CT, Sembower M, Ertischek MD, Shiffman S, Schnoll S

The new science of abuse-deterrence assessment of pharmaceutical products; FDA proposed guidance and Category 1 laboratory studies

Cone EJ, Buchhalter AR, Henningfield JE, Schnoll S

In the News

Pinney Associates’ Scientific Abuse Potential Assessment of Kratom Finds Evidence of Public Health Benefit and Little Harm

View PDF»

More Smokers Trying to Quit – PinneyAssociates’ Analysis of National Health Interview Survey Data Confirms Increase in Attempts to Quit Smoking

View PDF»

PinneyAssociates Presents at FDA Public Meeting to Help Facilitate the Development of Abuse Deterrent Opioids

Jack Henningfield and Sid Schnoll in National Pain Report: FDA Collaborative Approach Supports Abuse-Deterrent Opioids

View Article »

Learn what Ed Cone said about the FDA Abuse-Deterrent Guidance for Innovator and Generic Opioids

Watch Video »

PinneyAssociates Submits Comments to CDC on the 2016 Proposed Opioid Prescribing Guidelines for Chronic Pain

PinneyAssociates Offers ALERRT® Methodology for In Vitro Assessment of Abuse-Deterrent Formulations

View PDF »